

**Press Release**

**Vetbiolix completes a Series A fundraising of €4m and launches the European regulatory clinical development of its “First-in-class” drug candidates targeting osteoarthritis and canine and feline periodontitis**

**Lille, Monday December 02<sup>nd</sup> 2024** - Vetbiolix, a veterinary biotechnology company based in France, certified DeepTech France 2030, announces a fundraising of 4 million euros. The Series A round brings together the investment funds, CapTech Santé, Tudigo, Nord France Amorchage as well as management, and BPI France for the non-dilutive part.

This fundraising, which follows the excellent clinical results - known as proof of concept - generated by the company in 2024 on its First-in-class drug candidates VBX-1000 and VBX-2000, allows the company to launch in first quarter 2025 two double-blind randomized versus placebo regulatory pilot studies: the first on owned-dogs suffering from moderate to severe osteoarthritis (Study VBX2400-CL-2001) and the second on owned-dogs suffering from periodontitis (Study VBX1200-CL-2001). The funds raised will also be dedicated to the pharmaceutical development of VBX-1000 and VBX-2000 and to pursue the clinical development of VBX-3000 in intestinal motility disorders in dogs and cats.

**Matthieu Roquette, founder and President of Vetbiolix indicates:** *“We are very satisfied with this closing which exceeds the fundraising objectives that we had set for this Series A. This demonstrates the attractiveness of Vetbiolix which has very innovative drug candidates in its pipeline having demonstrated their effectiveness and safety of use for VBX-1000 and VBX-2000. We are now focused on the production of our next industrial deliverables expected by the veterinary pharmaceutical market and by the community of investors in the sector: in this case the results of our double-blind regulatory clinical studies vs. placebo expected for 2026.”*

**Matthieu Dubruque, founder and CEO of Vetbiolix, indicates:** *“With the clinical results generated in 2024 and this fundraising, Vetbiolix is positioning itself as a high-potential Vet Biotech player for the global Top 50 Pharma Vet with the possible perspective of co-developments and /or license transfers of our products by 2026. The same is true with investors targeting animal health. Alongside our efforts dedicated to generating quality clinical data on time, we will be very active in 2025 on Business Development discussions covering the entire spectrum of possible valuation options for Vetbiolix.”*

**About Vetbiolix – <https://www.vetbiolix.com>**

Vetbiolix develops innovative products for the treatment and prevention of diseases affecting pets. Vetbiolix has built a unique pipeline of several drug candidates, first in new classes of veterinary medications licensed (exclusive and worldwide license) from Biotechs Santé Humaine worldwide that will address unmet veterinary medical needs in the area of periodontitis, osteoarthritis and intestinal motility disorders. Vetbiolix focuses exclusively on the clinical developments of its drug candidates and invests in (i) proof-of-concept clinical studies, (ii) CMC-Pharmaceutical development, (iii) regulatory clinical pilot studies and (iv) clinical studies. Regulatory pivots. The company's revenue generation will be based on licensing and/or co-development agreements with the veterinary pharmaceutical industry.

**Contact: [matthieu.dubruque@vetbiolix.com](mailto:matthieu.dubruque@vetbiolix.com)**